The estimated Net Worth of Ventures V, L.P.5 Am Opport... is at least $20.7 Milión dollars as of 1 November 2021. Ventures Opport owns over 295,000 units of Cabaletta Bio Inc stock worth over $1,419,193 and over the last 4 years Ventures sold CABA stock worth over $19,324,000.
Sign up
Ventures Opport CABA stock SEC Form 4 insiders trading
Ventures has made over 4 trades of the Cabaletta Bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures sold 295,000 units of CABA stock worth $3,835,000 on 1 November 2021.
The largest trade Ventures's ever made was selling 625,000 units of Cabaletta Bio Inc stock on 7 September 2021 worth over $6,062,500. On average, Ventures trades about 401,250 units every 81 days since 2020. As of 1 November 2021 Ventures still owns at least 333,144 units of Cabaletta Bio Inc stock.
You can see the complete history of Ventures Opport stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Cabaletta Bio Inc
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over $19,324,000 worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth $13,043,398 . The most active insiders traders include Group, Llc Green Jeremy Red..., Ventures V, L.P.5 Am Opport... a James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of $632,329. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth $11,110.
What does Cabaletta Bio Inc do?
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
What does Cabaletta Bio Inc's logo look like?
Complete history of Ventures Opport stock trades at Cabaletta Bio Inc
Cabaletta Bio Inc executives and stock owners
Cabaletta Bio Inc executives and other stock owners filed with the SEC include:
-
Anup Marda,
Chief Financial Officer -
Steven Nichtberger,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Gwendolyn Binder-Scholl,
Executive Vice President, Science & Technology -
Dr. Steven A. Nichtberger M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Steven A. Nichtberger,
Co-Founder, Chairman, CEO & Pres -
Dr. David J. Chang M.D., M.P.H.,
Chief Medical Officer -
Dr. Gwendolyn K. Binder,
Exec. VP of Science & Technology -
Richard Henriques,
Independent Director -
Catherine Bollard,
Independent Director -
Mark Simon,
Independent Director -
Brian Daniels,
Independent Director -
David Chang,
Chief Medical Officer -
J. Brian Stalter,
General Counsel -
Michael Gerard J.D.,
Gen. Counsel & Sec. -
Heather Harte-Hall M.Sc.,
Chief Compliance Officer -
Michael Gerard,
Gen. Counsel -
Dr. Samik Basu M.D.,
Chief Scientific Officer -
Martha O'Connor,
Chief HR Officer -
J. Brian Stalter J.D.,
Gen. Counsel -
Dr. Aimee Payne M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Dr. Michael C. Milone M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Anup Marda M.B.A.,
Chief Financial Officer -
Shawn Tomasello,
-
Scott C. Brun,
-
Gwendolyn Binder,
See Remarks -
Arun Das,
Chief Business Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt Iv, ...,
-
Ventures V, L.P.5 Am Opport...,
-
Michael Gerard,
General Counsel